These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26416539)

  • 1. CAP--advancing the evaluation of preclinical Alzheimer disease treatments.
    Reiman EM; Langbaum JB; Tariot PN; Lopera F; Bateman RJ; Morris JC; Sperling RA; Aisen PS; Roses AD; Welsh-Bohmer KA; Carrillo MC; Weninger S
    Nat Rev Neurol; 2016 Jan; 12(1):56-61. PubMed ID: 26416539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials in predementia stages of Alzheimer disease.
    Pillai JA; Cummings JL
    Med Clin North Am; 2013 May; 97(3):439-57. PubMed ID: 23642580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subjective Cognitive Decline in Preclinical Alzheimer's Disease.
    Rabin LA; Smart CM; Amariglio RE
    Annu Rev Clin Psychol; 2017 May; 13():369-396. PubMed ID: 28482688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early identification of cognitive deficits: preclinical Alzheimer's disease and mild cognitive impairment.
    Small BJ; Gagnon E; Robinson B
    Geriatrics; 2007 Apr; 62(4):19-23. PubMed ID: 17408315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.
    Cavedo E; Dubois B; Colliot O; Lista S; Croisile B; Tisserand GL; Touchon J; Bonafe A; Ousset PJ; Rouaud O; Ricolfi F; Vighetto A; Pasquier F; Galluzzi S; Delmaire C; Ceccaldi M; Girard N; Lehericy S; Duveau F; Chupin M; Sarazin M; Dormont D; Hampel H;
    J Clin Psychiatry; 2016 Dec; 77(12):e1631-e1638. PubMed ID: 27780331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
    Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
    Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
    Teipel SJ; Cavedo E; Grothe MJ; Lista S; Galluzzi S; Colliot O; Chupin M; Bakardjian H; Dormont D; Dubois B; Hampel H;
    Neuropharmacology; 2016 Sep; 108():128-35. PubMed ID: 26876309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome.
    Startin CM; Hamburg S; Hithersay R; Al-Janabi T; Mok KY; Hardy J; ; Strydom A
    Alzheimers Dement; 2019 Feb; 15(2):245-257. PubMed ID: 30503169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.
    Reiman EM; Langbaum JB; Tariot PN
    Biomark Med; 2010 Feb; 4(1):3-14. PubMed ID: 20383319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
    De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
    J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.
    Lista S; Dubois B; Hampel H
    J Nutr Health Aging; 2015 Feb; 19(2):154-63. PubMed ID: 25651440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dementia of the Alzheimer type: non-drug and drug therapy].
    Kressig RW
    Ther Umsch; 2015 Apr; 72(4):233-8. PubMed ID: 25791046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ushering in the study and treatment of preclinical Alzheimer disease.
    Langbaum JB; Fleisher AS; Chen K; Ayutyanont N; Lopera F; Quiroz YT; Caselli RJ; Tariot PN; Reiman EM
    Nat Rev Neurol; 2013 Jul; 9(7):371-81. PubMed ID: 23752908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.